Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Cytometry. Part B, Clinical Cytometry
|
September 15, 2010
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL)
Andy C Rawstron, Tait Shanafelt, Mark C Lanasa, et al.
Cancer
|
September 12, 2013
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center
Lorenzo Falchi, Michael J Keating, Xuemei Wang, et al.
Blood
|
June 30, 2012
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans
Catherine C Coombs, Laura Z Rassenti, Lorenzo Falchi, et al.
British Journal of Haematology
|
August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients
John M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2019
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C Lanasa, Charles Farber, et al.
Blood
|
March 1, 2018
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Robert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Blood
|
October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia
Alan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Cancer
|
August 8, 2013
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)
Tait Shanafelt, Mark C Lanasa, Timothy G Call, et al.
Leukemia & Lymphoma
|
July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies
Daphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Cytometry. Part B, Clinical Cytometry
|
September 15, 2010
Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL)
Andy C Rawstron, Tait Shanafelt, Mark C Lanasa, et al.
Cancer
|
September 12, 2013
Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center
Lorenzo Falchi, Michael J Keating, Xuemei Wang, et al.
Blood
|
June 30, 2012
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans
Catherine C Coombs, Laura Z Rassenti, Lorenzo Falchi, et al.
British Journal of Haematology
|
August 23, 2014
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients
John M Pagel, Stephen E Spurgeon, John C Byrd, et al.
Journal for Immunotherapy of Cancer
|
August 25, 2019
Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
Daruka Mahadevan, Mark C Lanasa, Charles Farber, et al.
Blood
|
March 1, 2018
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Robert J Kreitman, Martin S Tallman, Tadeusz Robak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Blood
|
October 7, 2017
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia
Alan S Wayne, Nirali N Shah, Deepa Bhojwani, et al.
Cancer
|
August 8, 2013
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL)
Tait Shanafelt, Mark C Lanasa, Timothy G Call, et al.
Leukemia & Lymphoma
|
July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies
Daphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.
Page
of 4